Suchergebnisse - "García Layana, Alfredo"

PubPharm (6)

1

Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema : 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial

enthalten in: Japanese journal of ophthalmology | 2023

von Shimura, M. | Kitano, S. | Ogata, N. | +106

2

Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE) : two randomised, double-masked, phase 3, non-inferiority trials

enthalten in: Lancet (London, England) | 2022

von Heier, J. | Khanani, A. | Quezada Ruiz, C. | +115

CommentIn: Lancet. 2022 Feb 19;399(10326):697-699. - PMID 35085501

3

Evaluation of ranibizumab and aflibercept for the treatment of diabetic macular edema in daily clinical practice

enthalten in: PloS one | 2019

von Plaza-Ramos, P. | Borque, E. | García-Layana, A.

4

Association between CFH, CFB, ARMS2, SERPINF1, VEGFR1 and VEGF polymorphisms and anatomical and functional response to ranibizumab treatment in neovascular age-related macular degeneration

enthalten in: Acta ophthalmologica | 2018

von Cobos, E. | Recalde, S. | Anter, J. | +11

5

Single- and repeated-dose toxicity study of bevacizumab, ranibizumab, and aflibercept in ARPE-19 cells under normal and oxidative stress conditions

enthalten in: Biochemical pharmacology | 2016

von Saenz-de-Viteri, M. | Fernández-Robredo, P. | Hernández, M. | +4

6

Treatment of Exudative Age-related Macular Degeneration : Focus on Aflibercept

enthalten in: Drugs & aging | 2015

von García-Layana, A. | Figueroa, M. | Araiz, J. | +4

1
[1]